American College of Cardiology
56th Annual Scientific Session
New Orleans (Louisiana), 24-27 marzo 2007 		 
 
 
New implantable device effective in resistant hypertension
In patients with resistant hypertension, despite combination treatment, a new investigational device that electrically stimulates the body’s natural pressure-regulating sensors seems effective in reducing blood pressure.
 
Low-risk patients benefit from rosuvastatin treatment: METEOR study
Rosuvastatin was shown to halt disease progression in asymptomatic patients with moderately high cholesterol and low cardiovascular risk based on the criteria of the National Cholesterol Education Program Adult Treatment Panel (0 to 1 risk factor or >/=2 risk factors with a coronary disease risk < 10%).
 
Optimal medical therapy equally effective as PCI in stable angina: COURAGE trial
Outcomes in a large-scale clinical trial of patients with stable angina and coronary stenosis showed no survival benefit at 5 years with PCI compared to optimal medical therapy, with key outcomes similar with both strategies.
 
Secondary results of ARISE trial are promising, hypothesis generating
A study targeting inflammation acute coronary syndromes (ACS) with a novel treatment failed to meet its primary endpoint, but investigators believe the positive results for the secondary endpoints show promise for improving outcomes and provide valuable information for designing more trials with this agent.
 
Herbal medicinal substance delays death in heart failure in SPICE trial
The first morbidity and mortality trial with an herbal medicine proved the safety of the substance and that cardiac death was delayed.
 
Additive Blood Pressure Reduction with Novel Direct Renin Inhibitor plus Valsartan
A significant additional blood pressure reduction was obtained with the combination of aliskiren and valsartan, compared to either drug alone, in the first large-scale study to evaluate the effects of dual renin system blockade.
 
Phase III results with Investigational Drug Show Better Cardiac Peri-Operative Blood Pressure Control
Clevidipine, an intravenous antihypertensive agent, was shown to reduce the number of “blood pressure excursions”, how much and how long systolic blood pressure (SBP) went above or below predefined perioperative blood pressure ranges), compared to the currently used intravenous agents.

 
 
Legal
The materials presented here were prepared by independent authors under the editorial supervision of ESH online, and do not represent a publication of the American College of Cardiology. These materials and the related activity are not sanctioned by the American College of Cardiology and do not constitute an official part of that conference. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © ESHonline.org.